Neurology Department, Centre Hospitalier Universitaire, Hôpital Gui de Chauliac, 80 avenue Augustin Fliche, 34295, Montpellier, France.
Neuroradiology Department, Centre Hospitalier Universitaire, Montpellier, France.
Neuroradiology. 2022 Jun;64(6):1231-1238. doi: 10.1007/s00234-021-02849-x. Epub 2021 Nov 26.
The relationship between posterior-circulation lesion volume (PCLV) and clinical outcomes is poorly investigated. We aimed to analyze, in patients with acute basilar artery occlusion (ABAO), if pre-endovascular treatment (EVT) PCLV was a predictor of outcomes.
We analyzed consecutive MRI selected, endovascularly treated ABAO patients. Baseline PCLV was measured in milliliters on apparent diffusion-coefficient map reconstruction. Univariable and multivariable logistic models were used to test if PCLV was a predictor of 90-day outcomes. After the received operating characteristic (ROC) analysis, the optimal cut-off was determined to evaluate the prognostic value of PCLV.
A total of 110 ABAO patients were included. The median PCLV was 4.4 ml (interquartile range, 1.3-21.2 ml). Successful reperfusion was achieved in 81.8% of cases after EVT. At 90 days, 31.8% of patients had a modified Rankin scale ≤ 2, and the mortality rate was 40.9%. PCLV was an independent predictor of functional independence and mortality (odds ratio [OR]:0.57, 95% confidence interval [CI], 0.34-0.93 and 1.84, 95% CI, 1.23-2.76, respectively). The ROC analysis showed that a baseline PCLV ≤ 8.7 ml was the optimal cut-off to predict the 90-day functional independence (area under the curve [AUC] = 0.68, 95% CI, 0.57-0.79, sensitivity 88.6%, and specificity 49.3%). In addition, a PCLV ≥ 9.1 ml was the optimal cut-off for the prediction of 90-day mortality (AUC = 0.71, 95% CI, 0.61-0.82, sensitivity 80%, and specificity 60%).
Pre-treatment PCLV was an independent predictor of 90-day outcomes in ABAO. A PCLV ≤ 8.7 and ≥ 9.1 ml may identify patients with a higher possibility to achieve independence and a higher risk of death at 90 days, respectively.
后循环病变体积(PCLV)与临床结局之间的关系尚未得到充分研究。本研究旨在分析急性基底动脉闭塞(ABAO)患者中,血管内治疗(EVT)前的 PCLV 是否是结局的预测因素。
我们分析了连续入选的接受 MRI 选择并接受 EVT 治疗的 ABAO 患者。在表观弥散系数图重建上测量基线 PCLV,以毫升为单位。使用单变量和多变量逻辑模型来测试 PCLV 是否是 90 天结局的预测因素。在接收者操作特征(ROC)分析后,确定最佳截断值以评估 PCLV 的预后价值。
共纳入 110 例 ABAO 患者。PCLV 的中位数为 4.4ml(四分位距,1.3-21.2ml)。EVT 后,81.8%的患者实现了成功再灌注。90 天时,31.8%的患者改良 Rankin 量表评分为≤2,死亡率为 40.9%。PCLV 是功能独立性和死亡率的独立预测因素(优势比[OR]:0.57,95%置信区间[CI]:0.34-0.93 和 1.84,95%CI:1.23-2.76)。ROC 分析显示,基线 PCLV≤8.7ml 是预测 90 天功能独立性的最佳截断值(曲线下面积[AUC]:0.68,95%CI:0.57-0.79,敏感性 88.6%,特异性 49.3%)。此外,PCLV≥9.1ml 是预测 90 天死亡率的最佳截断值(AUC:0.71,95%CI:0.61-0.82,敏感性 80%,特异性 60%)。
治疗前 PCLV 是 ABAO 患者 90 天结局的独立预测因素。PCLV≤8.7ml 和≥9.1ml 可能分别识别出更有可能在 90 天达到独立性和更高死亡风险的患者。